Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

(2009) Y. H. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Immunosuppressive mechanisms in cancer: Consequences for the development of therapeutic vaccines

(2009) Stefanie Gross et al.   VACCINE

Immunomodulation of Breast Cancer via Tumor Antigen Specific Th1

(2009) Mary L. Disis et al.   Cancer Research and Treatment

Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?

(2008) Karin E. de Visser   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity

(2008) Y. H. Kim et al.   CANCER RESEARCH

An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer

(2008) P. Roepman et al.   CLINICAL CANCER RESEARCH

IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine

(2008) Jeffrey S Kennedy et al.   Expert Review of Vaccines

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

(2008) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates

(2008) Surojit Sarkar et al.   JOURNAL OF EXPERIMENTAL MEDICINE